SACUBITRIL; VALSARTAN | A213748 | MSN LABORATORIES PRIVATE LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Novartis Pharmaceuticals Corporation v. MSN Laboratories Private Limited et al 1 patentANDA 213748sacubitril/valsartan | D. Del. | 2025-01-17 | Active | — |
Novartis Pharmaceuticals Corporation v. MSN Pharmaceuticals Inc., et al 1 patentANDA 213682, 213605, 213748, 213646, 213671sacubitril/valsartan | D. Del. | 2022-10-24 | Terminated 2025-07-11 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$0.5859
per ea
Lowest NADAC/Unit
$0.5306
per ea
Brand NDCs
0
Generic NDCs
9
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 72205028218SACUBITRIL-VALSARTAN 97-103 MG | $0.5859 | EA | Generic | — | 2026-06-17 |
| 72205028260SACUBITRIL-VALSARTAN 97-103 MG | $0.5859 | EA | Generic | — | 2026-06-17 |
| 50268060813SACUBITRIL-VALSARTAN 97-103 MG | $0.5859 | EA | Generic | — | 2026-06-17 |
| 72205028160SACUBITRIL-VALSARTAN 49-51 MG | $0.5485 | EA | Generic | — | 2026-06-17 |
| 50268060715SACUBITRIL-VALSARTAN 49-51 MG | $0.5485 | EA | Generic | — | 2026-06-17 |
| 72205028118SACUBITRIL-VALSARTAN 49-51 MG | $0.5485 | EA | Generic | — | 2026-06-17 |
Showing 6 of 9 NDCs.
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.